HCR-188 / Helicore Biopharma - LARVOL DELTA

A First-in-human Study of HCR-188 in Overweight or Obese Otherwise Healthy Volunteers Without Type 2 Diabetes (clinicaltrials.gov) - P1 | N=48 | Suspended | Sponsor: Helicore Biopharma, Inc. | Trial completion date: Dec 2025 ➔ Dec 2027 | Recruiting ➔ Suspended

First-in-human • Trial completion date • Trial suspension • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Helicore Biopharma Announces First Participant Dosed in Phase 1 Clinical Trial of HCR-188, a First-in-Class GIP Antagonist for the Treatment of Obesity (GlobeNewswire) - "Helicore Biopharma Inc...announced today that the first participant has been dosed in its first-in-human Phase 1 study of HCR-188 for the treatment of obesity. HCR-188 is a first-in-class monoclonal antibody (mAb) designed to bind to circulating GIP ligand, unlike antibodies that bind the GIP receptor (GIP receptor antagonists)....Top-line safety data are anticipated in the second half of 2025."

P1 data • Trial status • Obesity

A First-in-human Study of HCR-188 in Overweight or Obese Otherwise Healthy Volunteers Without Type 2 Diabetes (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Helicore Biopharma, Inc.

New P1 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Helicore Biopharma Emerges from Stealth to Continue Advancing Portfolio of First-in-Class GIP Antagonists for Obesity and Related Conditions (GlobeNewswire) - "Helicore Biopharma Inc...announced today its emergence from stealth mode with $65 million in Series A financing. The round was co-led by founding investor Versant Ventures and by OrbiMed, with participation from Longitude Capital and Wellington Management....In order to connect human genetics with postulated biological pathways of GIP antagonism, Helicore has studied HCR-188 in combination with GLP-1 in preclinical models. Initial results of these studies suggest preferential loss of fat over lean mass, potentially enabling a higher quality of weight loss than can be achieved with GLP-1 alone....HCR-188, a clinic-ready antibody, entering first-in-human clinical studies with top-line data anticipated in the second half of 2025."

Clinical data • Financing • Preclinical • Obesity